Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
BTG: Numis reiterates buy with a target price of 840p
Looking better today, looking for a higher trading range maybe
thanks Volcano- the info is appreciated
there is a support around 590p but we will see what happens .
Early days after results but it's drifting down
Easily breeze to 700p. I give it a week or 2
This will hopefully pick up towards �7 again in a couple of weeks?????
Agree with oversold comments. Top up made yesterday. Still very cheap....... GLA
I know - check the date of my comment.....lol
This was announced on 5 April so nothing new!
Impairments presumably belong in the finance/accounts side so time to get a new accountant, unless of course this is a fiddle?
Hope the CEO reads this blog. Owned this share now for 5 years. Ŷear after year it promises things are all rosy when underneath that's clearly now not the case. Product after product gets delayed when taken to market. This latest one with a �150m impairment, acting like it doesn't matter as if it's a minor balance sheet adjustment. It's not, its basically the company sitting on a problem taking in costs then suddenly making a big adjustment as if they have only just realised. If that's true the management are incompetent, if not it's been a long term coverup of a product they knew the market wasnt ready or able (legal clearances) to buy. If this bounces up a bit I am out.
More like way way oversold. Everytime a company reports nowadays it seems to be the thing to knock it for 6 for absolutely no reason and leaves you wondering why you bothered in the first place.
another fine pick........
Bit of a red day today with market down. Hoping for good things preclose
Next update early April for May results. Looking at last update revenues are looking strong but not sure as to whether the company will make the leap in profits predicted for this year.
is looking good today
Having read this piece,I feel pretty uncomfortable with my holding.I feel the company has been more than �sparing� with the information provided to investors in recent years.Varithena is a disaster and won�t be marketed outside the USA and,in due course,a Mexican competitor could adversely hit BTGs anti venom money spinner. After the odd hiccup,Louise Makin is sure BTGs innovative treatments will power it into the FTSE 100 Extracts- “..........it has not been an easy couple of years.A much-hyped treatment for varicose veins was a flop,making just £1m in its first year after specialist vein clinics couldn’t get health insurers to reimburse them.Its bumbling launch in America led critics to question whether BTG had the ability to execute its shift from speciality pharmaceuticals to interventional medicine. “They were a little bit hoist by their own petard,�says Amy Walker ,an analyst at Peel Hunt.�Their presentations from 2014 featured doorstep wedges of projections between 2014 and 2021�.By far the biggest contributor was this new treatment ,she adds.�It was meant to be the turbocharge behind the shift.� BTG heralded the treatment-Varithena-as the biggest development in the vein market in 40 years.Makin has now slashed expectations and plans to market it only in America. When varithena was gaining momentum in the City,BTG was tipped to be on the fast track to the FTSE 100.Its shares had risen rapidly and revenues from new growth business were expected to reach $1.25bn by 2021.Since then the stock has stalled and expectations have been set at a more modest double digit growth for new business.Total revenues reached £570.5m last year. Makin....is elusive when asked if the hiccup has caused friction between BTG and its investors.. Today,it is interventional medicine which delivers chemotherapy directly to tumours,starved liver cancers or freezes them out completely that is earning BTG its stripes.Recent acquisitions include Roxwood,a US cardiovascular catheter maker it bought for $65m in October and Galil Medical,which treats tumours by forming an ice ball around the tissue. While BTG is bringing an eclectic mix of new treatments to market,it is its legacy snake venom business that has funded new innovations.The treatment-Crofab-could be under threat from a Mexican competitor that has developed a different treatment.Makin,however,is relying on the peace of mind BTGs anti venom business brings........�We’ve been on the market for 12 years,so we’ve saved 60,000 lives.We’re not complacent,we’re confidently paranoid.� Makin swerves questions about her tenure.Does she still have passion for the job?�Its taken me all this time to create the company that I want to run,and we’ve only just started.
Anyone know why this has fallen out of favour lately? thanks T
And the BTG ship goes bob, bob, bobbing along...........up.....and down...and up....and down.............
And now we have the answer, not MM's after all, but retail investors reacting to a broker downgrade
Steady decline on no news and unremarkable volume (with no visible bias) = potentially market makers playing with the numbers. The question is why are they doing it ?
Has someone offloaded a slug today if so not clear from share transactions ?
Oops that should have been for the PMG site
Results today from Parkmead (PMG) where increased production from the Diever West gas field to 39.3 million cubic feet a day gives positive cash flow and greater returns. Cash is a pleasing $34.3 million (�26 million) and Tom Cross is maintaining his usual strict discipline. For right or for wrong he has increased his position in the Greater Perth area and activity covering pre-FEED and FEED is under way. I took PMG out of the bucket list in February at over 60p, as I couldnt see the market liking the play as much as others, at 37p today I still need convincing that they offer substantial value.